Synaptic Protective Therapies For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Synaptic Protective Therapies for Neurodegeneration [1]
| Property | Value | [2]
|----------|-------| [3]
| Category | Disease-Modifying Therapy | [4]
| Targets | Synaptic proteins, NMDA/AMPA receptors, BDNF signaling, Synaptogenesis | [5]
| Diseases | Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, ALS, FTD | [6]
| Mechanism | Protect synapses from degeneration, promote synaptogenesis, enhance synaptic plasticity | [7]
| Development Stage | Preclinical to Phase II |
Synaptic loss is a hallmark of neurodegenerative diseases and correlates strongly with cognitive decline. Synaptic protective therapies aim to preserve synaptic structure and function, enhance synaptic plasticity, and promote the formation of new synaptic connections.
| Target | Function | Dysfunction in Disease |
|---|---|---|
| PSD-95 | Postsynaptic scaffolding | Reduced in AD/PD |
| Synaptophysin | Synaptic vesicle protein | Marker of loss |
| SNARE proteins | Neurotransmitter release | Impaired in ALS |
| NMDA receptors | Synaptic plasticity | Dysregulated in AD |
| AMPA receptors | Fast excitatory transmission | Reduced in AD |
| BDNF/TrkB | Synaptic growth factor | Deficient in AD/PD |
| Drug | Mechanism | Status |
|---|---|---|
| Memantine | Uncompetitive NMDA antagonist | Approved (AD) |
| Azinpilizumab | Anti-NMDAR antibody | Research |
| Neramexane | NMDA antagonist | Phase II |
| Rapastinel | TrkB modulator | Research |
| Compound | Mechanism | Status |
|---|---|---|
| CX516 | AMPA PAM | Research |
| CX717 | AMPA PAM | Phase I |
| LY451395 | AMPA PAM | Research |
| Factor | Target | Status |
|---|---|---|
| BDNF | TrkB | Phase II (failed) |
| NT-3 | TrkC | Research |
| GDNF | GFRα1/RET | Research |
| Cerebrolysin | Multiple | Approved (EU/Asia) |
| Compound | Target | Status |
|---|---|---|
| Lithium | GSK-3β, NMDA | Approved (mania) |
| Minocycline | Microglia | Research |
| Rolipram | PDE4 | Research |
Synaptic protection strategies:
Clinical evidence:
Focus areas:
Approaches:
Targets:
Synaptic protectors may combine with:
The study of Synaptic Protective Therapies For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Li S, et al. Soluble Aβ oligomers impair synaptic plasticity by disrupting NMDA receptor-mediated signaling. Nature Neuroscience. 2009. ↩︎
Blennow K, et al. Synaptic pathology in Alzheimer's disease: A novel therapeutic target. Lancet Neurology. 2021. ↩︎
Mangialasche F, et al. Memantine in moderate-to-severe Alzheimer's disease: A systematic review. CNS Drugs. 2020. ↩︎
Rockenstein E, et al. Cerebrolysin: A multi-target drug for neurodegenerative disorders. Journal of Neural Transmission. 2021. ↩︎
Lu B, et al. BDNF and synaptic plasticity. Nature Reviews Neuroscience. 2013. ↩︎
Catterall WA, et al. Synaptic dysfunction in neurodegenerative diseases. Neuron. 2020. ↩︎
Zhou Q, et al. Synaptic protection and repair. Neuron. 2021. ↩︎